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Summary
Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis 
and limited treatment options. Here, we describe the integrated analysis of somatic mutations, 
RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of 
predominantly intrahepatic CCA cases and propose a molecular classification scheme. We 
identified an IDH mutant-enriched subtype with distinct molecular features including low 
expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased 
mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A 
exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More 
broadly, we found that IDH mutations are associated with an expanded histological spectrum of 
liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the 
molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification 
information of potential therapeutic significance.
Graphical abstract
Introduction
Cholangiocarcinomas (CCAs) are a group of malignancies of the biliary epithelium 
(cholangiocytes), comprising invasive carcinomas that arise in the intrahepatic, perihilar, and 
extrahepatic biliary tree (Razumilava and Gores, 2014). Most patients with CCA present 
with advanced disease and have a median survival of less than 1 year despite treatment with 
current standard chemotherapy (Valle et al., 2010). Even patients who undergo apparently 
curative resection have poor outcomes due to a high rate of tumor recurrence (Razumilava 
and Gores, 2014). Although intrahepatic, perihilar, and extrahepatic CCAs share 
morphologic features and have traditionally been aggregated in clinical trials, it is now 
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apparent that there are important differences in tumor biology and genetics among tumors 
from different anatomic sites (Chan-On et al., 2013; Churi et al., 2014). Further elucidation 
of molecular alterations in these heterogeneous tumors and discovery of meaningful 
subtypes within each anatomic group are important steps toward developing more rational, 
specific, and effective treatments (Kelley and Bardeesy, 2015).
Cholangiocarcinoma is the second most common type of primary liver tumor, and its 
incidence has been rising in the United States, from 0.44 per 100,000 in 1973 to 1.18 in 
2012 (Saha et al., 2016). The actual incidence of the disease is likely much higher, as recent 
gene expression studies suggest that “carcinomas-of-unknown primary” identified in the 
liver most commonly originate from biliary epithelium (Varadhachary and Raber, 2014). 
Worldwide, the highest incidence of CCA is found in northeastern Thailand, where parasitic 
infection by liver flukes (Clonorchis sinensis and Opistorchis viverrini) leads to infestation 
of the biliary tree (Razumilava and Gores, 2014). In regions without liver fluke infestation, 
CCA disease etiologies include: primary sclerosing cholangitis, hepatitis B or C virus (HBV/
HCV) infection, biliary stone disease, congenital biliary malformations, cirrhosis, and 
exposure to aromatic toxins (Razumilava and Gores, 2014). Lifestyle-related factors such as 
smoking, alcohol consumption, and diabetes also contribute to the risk of intrahepatic CCA 
(iCCA) (Palmer and Patel, 2012). Given the diversity of risk factors influencing the 
mutational spectrum and the distinct cellular origins of the CCA subtypes, there is still an 
incomplete appreciation of the mechanisms of biliary carcinogenesis.
Prior studies indicate that iCCAs are unusual among epithelial cancers in having a relatively 
high rate of missense mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes 
(Borger et al., 2012; Chan-On et al., 2013; Jiao et al., 2013; Kipp et al., 2012; Ross et al., 
2014; Wang et al., 2013), which encode metabolic enzymes that interconvert isocitrate and 
alpha-ketoglutarate in central carbon metabolism. These mutations, which are also common 
in acute myeloid leukemia, low-grade glioma and glioblastoma, and chondrosarcoma, occur 
at defined hotspots and result in neomorphic enzyme activity, leading to production of high 
levels of the metabolite (R)-2-hydroxyglutarate (2HG) (Losman and Kaelin, 2013). 2HG 
does not participate in normal metabolic processes but instead interferes with the function of 
enzymes that utilize alpha-ketoglutarate as a co-enzyme, including histone and DNA 
demethylases, and inhibits the mitochondrial electron transport chain (Fu et al., 2015; Parker 
and Metallo, 2015). Additional recurrent mutations and fusions have been reported in CCAs 
involving the fibroblast growth factor receptor 2 (FGFR2) gene, as well as in KRAS, BRAF, 
TP53, and in genes encoding chromatin-modifying enzymes (Borad et al., 2014; Churi et al., 
2014; Jiao et al., 2013; Nakamura et al., 2015; Ross et al., 2014; Sia et al., 2015). Given this 
complexity, it is imperative to generate a more integrative model of the molecular alterations 
in iCCA to better define the oncogenic circuitry and to derive a classification system that 
groups tumors into biologically meaningful subtypes that can be used to guide therapy.
In this study, we describe molecular features of 38 liver fluke-negative CCAs—
predominantly intrahepatic and hepatitis negative—that stratify the disease into distinct 
groups. Most notably, we identify a class of CCAs with distinct transcriptomic, copy 
number, and methylation profiles that are highly enriched for IDH mutant samples. We also 
identify pathways and methylation patterns that we validate in external datasets and which 
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could help lead to the development of more effective treatments. Finally, cross-platform 
comparisons of CCA with pancreatic cancer and hepatocellular carcinoma (HCC) further 
emphasize the presence of distinct tumor subsets.
Results
Samples
We analyzed 38 CCA samples that were predominantly from North America (89%), 
intrahepatic (84%), fluke-negative (100%), and HBV/HCV-negative (97%, as assessed by 
combined DNA and RNA sequencing, which also revealed no HBV integration sites), and 
had no prior exposure to chemotherapy or radiation (Tables 1 and S1). This relative overall 
sample uniformity minimizes known and potential sources of molecular heterogeneity in our 
sample set.
The TCGA analysis pipeline used in this study consists of the following platforms: 
wholeexome sequencing; Affymetrix SNP 6.0 copy number array; RNA sequencing (RNA-
seq), including microRNA (miRNA) and long noncoding RNA (IncRNA); DNA 
methylation; and reverse-phase protein array (RPPA) utilizing 192 antibodies. These datasets 
are annotated with relevant clinical information and careful histopathologic review by 
several experienced hepatobiliary pathologists (Table S1).
Gene-Level Mutations, Fusions, and Copy Number Alterations
We first annotated alterations to specific genes. Whole-exome sequencing identified 2,831 
somatic mutations, of which 1,869 (66%) were non-silent coding mutations. Targeted-
capture, deep sequencing validation of 43 selected genes confirmed 77 mutations and newly 
identified nine (see Supplemental Experimental Procedures and Table S2). The median 
mutation rate was 1.38 per megabase, with a median mutation count of 49 (Figure 1A; Table 
S1). Compared to other cancers assessed by TCGA (Lawrence et al., 2013), this CCA 
mutation rate is intermediate, and comparable to that of pancreatic ductal adenocarcinoma 
(PDAC).
Consistent with previous studies, we identified inactivating mutations in the tumor 
suppressor genes ARID1A, ARID1B, BAP1, PBRM1, TP53, STK11, and PTEN, and 
hotspot gain-of-function mutations in the oncogenes IDH1, IDH2, KRAS, BRAF, and 
PIK3CA (Figures 1A and S1A; Tables S1 and S3). Also consistent with prior reports, the 
IDH mutant alleles described in our cohort (IDH1R132C and IDH2R172K/S) are distinct from 
those found in glioma and acute myeloid leukemia (enriched for IDH1R132H and 
IDH2R140Q) (Cancer Genome Atlas Research Network, 2013; Brat et al., 2015). In two 
tumors, we identified a recurrent P216L mutation in the regulatory domain of ARAF 
adjacent to the functionally validated N217I mutation (Sia et al., 2015), which suggests an 
activated state. We also identified two frameshift deletions and one missense mutation 
S217F (Zou et al., 2014) in the albumin gene (ALB), one of the most significantly mutated 
genes in HCC (Schulze et al., 2015). Finally, we detected a single telomerase reverse 
transcriptase (TERT) promoter mutation, in a mixed HCC/iCCA sample. To further validate 
the observed mutations, we performed whole-exome sequencing and targeted deep 
Farshidfar et al. Page 5
Cell Rep. Author manuscript; available in PMC 2017 June 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
validation on an independent set of 15 samples (Figure 1B). Although analyzed separately, 
these additional samples corroborated the mutations above and highlighted additional 
recurrent mutations in the BRCA2, MLL3, APC, NF1, and ELF3 tumor-suppressor genes.
An analysis of gene fusions from RNA-seq data identified five samples (13%) that expressed 
FGFR2 fusion transcripts; this prevalence is consistent with other studies (Arai et al., 2014; 
Churi et al., 2014; Goyal et al., 2016; Nakamura et al., 2015; Ross et al., 2014). Our cases 
included two with the known fusion partner BICC1 and three with the partners KIAA1598, 
FRK, and C10ORF118 (Table S3). Other than the FGFR2-FRK fusion, which resulted in 
loss of the FGFR2 kinase domain and retention of the FRK kinase domain, the rest of the 
fusions retained the kinase domain, consisting of FGFR2 exons 1–17 spliced in frame with 
the partner gene. We note that BICC1, KIAA1598, and C10ORF118 are located on 
chromosome 10 along with FGFR2. We also observed two missense mutations and one in-
frame insertion in FGFR2.
Somatic copy number alterations (SCNAs) determined by analysis of high-density SNP data 
identified recurrent focal losses of CDKN2A and amplifications of CCND1. We further 
identified low-prevalence cases of focal SCNAs that have been reported in other cancers, 
including amplification of CDK4/MDM2 and homozygous focal deletion of QKI and SAV1 
(Table S1; Figure S1B). The functional perturbation of these genes is supported by 
correlative gene expression data (Figure S1C). Epigenetic silencing of CDKN2A was 
identified in eight cases (21%) and was mutually exclusive with homozygous deletions and 
mutations (Figures 1, S1D, and S1E). Collectively, CDKN2A was mutated, deleted, or 
silenced in 47% of cancers, a higher rate than previously appreciated with single platform 
analyses.
Next, cross-comparing sequencing and copy number data, we found that all mutations in 
BAP1 and PBRM1 (both located on 3p21) were detected in tumors with 3p loss of 
heterozygosity, suggesting biallelic inactivation of these genes in near-diploid tumors. 
Cancer cell fractions were higher for the broad or arm-level loss of chromosome 3 than for 
BAP1 mutations, followed by PBRM1 mutations, suggesting that these events occur 
chronologically (3p loss, BAP1, PBRM1) in CCA development (Figures S1F and S1G). We 
also note that the NF2 splice site mutation in sample AA0S experienced loss of 
heterozygosity, suggesting bi-allelic loss of this Hippo pathway tumor suppressor gene.
Finally, using a previously defined mutational signature assessment (Covington et al., 2016) 
and non-negative matrix factorization, we identified seven enriched mutation signatures out 
of 21 total signatures. As observed across 31 tumor types analyzed to date (Covington et al., 
2016), the most common signature was C > T/G > A substitutions at CpG islands (signature 
#6), followed by signature #1, characterized by AC > AN, AT > AN (Figure 1).
Filtering Normal Liver Genes Uncovers an IDH-Mutant-Enriched mRNA Subgroup
We next analyzed mRNA expression by unsupervised hierarchical clustering, selecting only 
the most variable 2% (i.e., 400) of genes. The two resultant clusters showed a large 
differential expression of the genes (Figure S2A) with strong enrichment for a liver-
associated signature. However, the clusters did not correlate with any other molecular or 
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clinical parameter. Given that most liver signature genes are expressed in normal liver at 
levels 1,000- to20,000-fold higher than in tumors, we considered that the liver signature 
expression in part reflected contamination by even a small amount of normal liver. 
Consistent with this hypothesis, histological analysis revealed a trend toward higher normal 
liver contamination in the liver-high cluster (Figure S2C), which was not picked up by 
DNA-based tumor purity estimates. This indicates that high-expressing stromal genes likely 
confound mRNA expression clustering, particularly when using only the top-most variable 
genes.
To reduce the statistical effects of the liver signature, 386 liver-specific genes derived from 
the GTEx (Genotype-Tissue Expression) normal tissue expression database (Lonsdale et al., 
2013) (Table S4) were filtered out. The remaining 15,427 genes underwent principal 
component analysis (PCA) (Figures 2A and 2B), identifying three clusters. A subset of 
1,150 genes was identified by orthogonal partial least-squares discriminant analysis 
(OPLSDA) as most strongly contributing to cluster separation (Figure 2A). Intriguingly, 
cluster 1 included all seven cases with an IDH1 or IDH2 hotspot mutation, while cluster 2 
was enriched in extrahepatic or perihilar CCA, and cluster 3 contained all five FGFR2 
fusions. This was validated by comparison with the previously generated microarray gene 
expression dataset GSE26566 (Andersen et al., 2012; Wang et al., 2013). Hierarchical 
clustering was performed for the 976 most strongly discriminant genes shared between 
datasets (Figure 2C). In this validation cohort of 40 samples, three main clusters were 
identified that resembled the TCGA dataset clusters. Notably, most IDH1/2 mutations (eight 
of ten) were located in the cluster that most strongly resembled the IDH-mutant-enriched 
TCGA cluster 1. Thus, removal of the liver signature unmasked transcriptional clusters that 
segregated samples in a biologically relevant manner.
The IDH Mutant Subgroup Is Enriched for Mitochondrial and Chromatin-Modifier 
Signatures
We next performed gene set enrichment analysis (GSEA) on the mRNA clusters and 
discovered an enriched expression of genes involved in mitochondrial structure and function 
in the IDH-mutant-enriched cluster 1. This included notable upregulation of genes encoding 
citric acid cycle enzymes, mitochondrial ribosomal proteins, electron transport chain 
components, and mitochondrial structural constituents, consistent with altered control of 
oxidative phosphorylation and mitochondrial biogenesis (Figure 3A; Tables S5 and S6) 
(hereafter collectively referred to as “mitochondrial gene expression”). High mitochondrial 
gene expression was significantly associated with IDH and PBRM1 mutant samples and low 
expression with FGFR2-fusion samples (Figure 3B and depicted as a condensed 
“mitochondrial score” in Figure 3D); these correlations were improved by removing low-
purity (<0.65) samples, a possible confounding factor (Figures S3A and S3B). In keeping 
with potential functional relevance of the differential expression of mitochondrial genes, we 
identified a relatively higher mitochondrial copy number (Reznik et al., 2016) in IDH mutant 
samples and a lower number in FGFR2-fusion samples (Figure 3E).
Examination of the GSE26566 dataset (Andersen et al., 2012) provided an external 
validation of these findings, again identifying an enrichment of IDH mutants among the 
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tumors with high expression of the mitochondrial gene signature (Figure 3C). This 
association between this signature and IDH mutations appears to be particular to CCA, since 
it was not observed upon analysis of TCGA datasets for glioblastoma, low-grade glioma, 
melanoma, or acute myeloid leukemia TCGA datasets (Figure S3C).
GSEA also identified chromatin modifier gene sets as significantly downregulated in the 
IDH mutant mRNA cluster (Figure 3A; Tables S5, S6, and S7. Notably, these included genes 
recurrently mutated in CCA—ARID1A, ARID1B, and PBRM—as well as genes whose 
protein products are known to be inhibited by IDH-mutant-generated 2HG, including TET2, 
TET3, KDM2A, and KDM5B (Xu et al., 2011). Expression of the chromatin modifier 
geneset anticorrelated with the mitochondrial geneset even when considered as a gradient 
(Figure S3D; Table S7). Querying of this association in multiple TCGA gene expression 
datasets demonstrated strikingly consistent anticorrelation of these two pathways across 23 
of 25 cancer types (Figure 3F) as well as across and within normal tissues (Figure S3E) from 
the GTEx database for most genes. These results suggest that mitochondrial activity and 
chromatin modification are linked basic biological events that are also regulated by IDH 
hotspot mutations in CCA.
Cluster-of-Clusters Analysis Identifies Four Subgroups
We next enlisted the additional platforms (copy number, methylation, miRNA, IncRNA, and 
protein) into a clustering of the cluster assignments (COCAs) (Hoadley et al., 2014), which 
provides a way to distinguish sample subtypes by identifying patterns across platforms. We 
started by performing hierarchical clustering of each platform separately. First, copy number 
based on SNP array hybridization data (Figure 4A) revealed four genomic clusters. We note 
that this clustering is performed on select SCNAs determined by genome identification of 
significant targets in cancer (GISTIC) analysis to be significantly differentially altered, as 
using all data points results in overfitting. This approach therefore highlights samples that 
share loci that are likely undergoing positive selection in the tumor. Cluster 4 consisted 
entirely of tumors with high-level amplification of CCND1. Cluster 2 was characterized by 
enrichment of chromosomal deletions, particularly 6q, 9, and 14. Cluster 3 tumors contained 
mostly SCNAs that were found across the larger set of tumors (e.g., 1p loss and 1q gain), but 
on average had fewer arm-level deletions than cluster 2. Last, cluster 1 consisted of 
molecularly atypical tumors, including two genomically silent cases that were completely 
devoid of copy number alterations or recurrent CCA driver mutations (the low-purity 
extrahepatic W5-AAH2 and the 0.61-purity intrahepatic ZH-A8Y6).
Next, unsupervised clustering of samples using CpG sites that show cancer-specific DNA 
methylation changes identified four subgroups in our CCA cohort (Figure 4B). Tumors in 
cluster 1 showed minimal alterations in DNA methylation compared with normal liver, 
which is at least partially explained by low tumor purity for most of the samples. The 
remaining tumors had prominent DNA hypermethylation and were classified into three 
subgroups. All seven IDH mutant tumors were present in cluster 4, along with one IDH-
wild-type case that exhibited a gene expression profile similar to that of IDH mutants (see 
Figure S4A). Surprisingly, on average, tumors in cluster 2 showed an even greater degree of 
DNA hypermethylation than did IDH mutant tumors (Figures 4B and S4B). Last, we note 
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that tumors in clusters 2 and 3 had frequent mutation of genes encoding chromatin 
regulators, including PBRM1 and ARID1A (ten of 20).
We observed that the copy number and methylation clusters generally matched the mRNA 
clusters identified in Figure 3, suggesting the ability of the data to detect shared biological 
mechanisms. By contrast, hierarchical clustering of mature miRNAs, IncRNAs, and protein 
yielded clusters that were discordant with the other platforms. We believe this is mainly due 
to the far smaller number of informative features available for clustering (169, 101, and 192, 
respectively) given the sample size (Figure S4). As expected, COCA analysis using all six 
platforms gave a discordant pattern with no clinical correlates, even when the lower-sample 
number RPPA was removed. We therefore conducted the COCA analysis using only mRNA, 
copy number, and methylation to discern biologically coherent clusters. We optimized a 
four-cluster solution (see Experimental Procedures) that was not dominated by any one 
platform (Figure 4C).
We then correlated clinical data and molecular aberrations with the four COCA clusters 
(Figure 4C; Table S1). IDH hotspot mutations were present exclusively in COCA2 (p = 
0.0004; “IDH COCA”), reflecting the mRNA and methylation specificity noted earlier, and 
identifying a correlation with copy number cluster 2 (“genomically unstable”). Patients with 
IDH COCA tumors were typically nonsmokers, and the tumors exhibited a lower frequency 
of lymphatic invasion and chromosome arm 8p gains (Figure 4C). Three of four distal or 
hilar tumors were in COCA1 (p = 0.003; “ECC COCA”), which exhibited the following 
characteristics: wild-type for FGFR2, IDH1/2, ARID1A, BAP1, and PBRM1; low 
methylation; and relative genomic silence for copy number alterations. COCA3 was 
enriched for samples with CCND1 amplification and with the most highly hypermethylated 
profile (methylation cluster 2; “METH2 COCA”). COCA4 (“METH3 COCA” contained 
eight of 12 cases with BAP1 mutations (p = 0.01) and all five FGFR2 fusion cases (p = 
0.004). Survival analysis among the COCA clusters did not yield significant p values, 
possibly due to the small sample size. All clustering solutions for individual platforms and 
for COCAs, as well as key genetic, clinical, and pathologic data are available in Table S1. 
We posit that these COCAs identify biologically distinct CCA subtypes with potential 
clinical implications; however, we also acknowledge the limitations due to the sample 
number, and that validation of these subtypes awaits new comparable datasets and functional 
confirmation in model systems. Nevertheless, these results clearly highlight the molecular 
distinctness of IDH mutants and the power of integrated multiplatform analyses.
ARID1A Promoter Hypermethylation and Decreased Expression in IDH Mutants
To extend our analysis of the IDH mutant subgroup, we considered that the COCA 
classifications may help reveal new cross-platform insights. To this end, we asked whether 
IDH-mutant-specific DNA hypermethylation may target genes that show decreased 
expression in the IDH COCA subtype. We restricted the analysis to high-purity samples to 
avoid assessing gene expression changes that are primarily associated with contaminating 
stroma rather than with methylation. After intersecting IDH mutant hypermethylated loci 
with genes with decreased expression in the IDH COCA subtype and filtering for gene-
specific anticorrelation between the two platforms, we identified a list of 24 genes whose 
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expression is putatively regulated by IDH mutant hypermethylation (Figures 5A and 5B). To 
validate this list, we cross-referenced it with the matched CCA methylation and expression 
datasets GSE32079 and GSE26566, respectively (Andersen et al., 2012; Wang et al., 2013). 
GSE32079 uses the same methylation array platform as the TCGA dataset, allowing for 
direct comparison of probes. While all 24 genes once again showed IDH-mutant-specific 
hypermethylation (Figure 5C), only three genes, ARID1A, MARVELD1, and SLC1A5 were 
significantly downregulated (Figure 5D) in the “IDH-like” mRNA cluster (cf. Figure 2C). 
Given the bona fide tumor suppressor role of ARID1A in the liver, we explored the 
relationship between DNA methylation and expression further (Figure 5E). Of four IDH-wt 
samples in the IDH COCA, two were ARID1A mutant with low ARID1A expression. 
Moreover, the only IDH mutant to not show ARID1A hypermethylation, A95A, was 
ARID1A mutant with low expression (Figures 5A and 5E), suggesting that ARID1A 
mutation and IDH-induced hypermethylation are mutually exclusive due to redundancy. 
Analysis of publically available histone modification ChIP-seq data showed that the two 
hypermethylated ARID1A probes were located in the ARID1A promoter within the active 
transcription marks H3K27Ac and H3K4me3 (Figure 5F). Collectively, these data suggest 
that IDH mutations result in hypermethylation and silencing of ARID1A, and that 
impingement of ARID1A is a convergent feature of IDH COCA tumors.
IncRNAs Associated with the Chromatin Modifier Signature
Given the centrality of the chromatin modifier signature to the IDH COCA subtype, we 
explored the remaining platforms to identify non-mRNA members of the signature. As 
IncRNAs are relatively understudied, we sought to identify IncRNAs that correlated with the 
mRNA-based chromatin modifier signature. To further limit the resulting set of 66 IncRNAs, 
we asked which ones also tracked with the chromatin modifier signature across other TCGA 
datasets (cf. Figure 3F). Across eight assessed cancers, we found that 21 of the IncRNAs 
correlated with the chromatin modifier signature in at least six cancers (Figure S5A; Table 
S7). Importantly, only an estimated eight of the 66 IncRNAs were expected to correlate by 
chance, making 21 a significant enrichment (p = 0.01, Fisher's exact test). These findings 
suggest potential functions for these 21 IncRNAs, which have not previously been studied.
Additionally, we identified IncRNA clusters that correlate with immune and liver mRNA 
signatures (Figures S5B and S5C) in the CCA dataset. To validate these, we determined the 
overlap with high-stringency immune- and liver-specific IncRNAs defined from the GTEx 
database (Lonsdale et al., 2013): for immune-associated IncRNAs, 34/48 CCA-derived 
IncRNAs overlapped with 190 GTEx IncRNAs (p = 2 × 10-13), while for liver-associated 
IncRNAs, 25/25 CCA-derived IncRNAs overlapped with 127 GTEx IncRNAs (p = 4 
×10-13). These clusters lend support to the biological fidelity and analytical utility of the 
IncRNA platform and provide starting IncRNA candidates when analyzing future samples. 
For miRNAs, we note that miRNA-194-5p is significantly upregulated in the IDH COCA 
subtype and negatively correlated with the chromatin modifier signature (Figures 4 and 
S5D–S5H). Notably, miRNA-194 has been implicated as a suppressor of invasion in liver 
cancer in vitro (Meng et al., 2010). The results of these analyses collectively demonstrate the 
robustness of the pan-cancer and cross-platform capacity of the TCGA.
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Comparison with HCC and PDAC
We next compared liver, pancreatic, and biliary cancer across the standardized multiplatform 
TCGA datasets to determine their molecular relationships (Borad et al., 2014). First, to 
improve comparisons of mutational landscapes, we conducted a meta-analysis of six iCCA 
sequencing studies (Churi et al., 2014; Jiao et al., 2013; Nakamura et al., 2015; Ruzzenente 
et al., 2016; Zou et al., 2014) including this one, totaling 458 samples (Table S8). Whereas 
PDAC is dominated by KRAS (92%) and TP53 (70%) mutations, KRAS/NRAS and TP53 
mutations comprise only 20% and 21% of iCCAs, respectively. HCC is characterized by 
TERT promoter (46%) and CTNNB1 (26%) mutations, neither of which are present in 
iCCA; otherwise HCC shares only three genes with iCCA that are mutated at >5% (TP53, 
BAP1, and ARID1A).
We next applied the Tumor Map algorithm, which generates “islands” of cancers based on 
similarity within chosen platforms (Davis et al., 2014). Incorporating mRNA expression, 
copy number, and methylation data (Figure 6A), this analysis separated most HCC, PDAC, 
and CCA samples into their respective cancer-type islands; however, seven of 38 (18%) 
CCA samples were embedded in the PDAC and HCC islands, and seven of 179 (4%) HCC 
samples were embedded in the CCA island, suggesting that some samples have discordant 
histopathologic and molecular profiles.
To better understand these discordances, we illustrated cluster memberships for all 292 
CCA/HCC/PDAC samples (Table S9) after clustering within each molecular platform 
(mRNA, miRNA, RPPA, copy number, and methylation; Figures S6A–S6F). First, we noted 
that most of our COCA1 CCA samples (distal/hilar CCA-enriched) clustered with PDAC, 
consistent with the related developmental origins of the extrahepatic and pancreatic ducts 
from the foregut endoderm. Second, we studied in greater depth the seven HCCs that 
mapped with CCA. These tumors shared several molecular features with CCA, including 
mRNA and miRNA expression patterns, DNA methylation, and to a lesser extent copy 
number (Figure 6B). Moreover, they lacked TERT promoter mutations, which are a hallmark 
of HCC but are absent in CCA. Strikingly, five of those seven samples harbored either 
hotspot IDH1/2 mutations (n = 4) or an FGFR2 fusion (n = 1), and they were the only cases 
in the HCC dataset with these mutations. Re-examination of their histology revealed that 
although regions of these seven cases fall within the spectrum of HCC, each of the five 
tumors with IDH1 or FGFR2 lesions had some features that have also been described in 
iCCA, including focal to diffuse glandular differentiation, abundant fibrotic stroma 
(desmoplasia), and in some areas, an anastomosing architecture (Figures S6G–S6L) 
(Bledsoe et al., 2015; Liau et al., 2014; Nakanuma et al., 2012). Consistent with this, these 
samples expressed bile duct (e.g., SOX9) and hepatocellular (e.g., HNF4A, HNF1A) 
markers at levels within that of iCCA (Figures 6C, S6M, and S6N). Analysis of the 600 
genes that are most enriched in these tumors compared with standard HCC corroborated this 
close transcriptional similarity to CCA (Figure 6C). These data are notable in view of 
accumulating evidence that CCA and HCC lie along a spectrum of primary liver carcinomas, 
with intermediate subsets exhibiting overlapping phenotypes. The prominent enrichment of 
IDH mutations in molecularly CCA-like HCCs is consistent with previous findings that IDH 
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mutations block liver progenitor cells from undergoing hepatocyte differentiation and shift 
them toward a cholangiocellular fate (Saha et al., 2014).
Discussion
Taking advantage of the molecular resolution provided by multiple genomic platforms, we 
identified distinct mRNA, DNA methylation, and copy number subgroups that together 
specify biologically relevant CCA classes. In particular, we highlight an IDH-mutant-
enriched class whose samples share similar profiles across these three platforms. Notably, 
this class exhibits high expression of mitochondrial genes, including components of the 
citric acid cycle and electron transport chain, accompanied by relatively high mitochondrial 
DNA copy number, as well as low expression of chromatin modifier genes. This 
anticorrelation of mitochondrial and chromatin modifier signatures appears to be a basic 
biological link spanning nearly all TCGA cancers and normal GTEx tissues analyzed 
(Figures 2F and S9), warranting deeper mechanistic studies. The anticorrelation is consistent 
with the hypothesis that global changes in histone acetylation and DNA methylation rates 
affect mitochondrial metabolism via imbalances in available pools of acetyl and methyl 
moieties (Martinez-Pastor et al., 2013). Relevantly, IDH mutants hypermethylate and 
putatively silence the ARID1A promoter, which may contribute to the lowered chromatin 
modifier signature expression.
Moreover, we identify a group of liver tumors with an atypical histopathology and a highly 
CCA-like molecular profile that is enriched for IDH mutations, consistent with the emerging 
view that liver tumors comprise a continuous spectrum (Fan et al., 2012; Holczbauer et al., 
2013; Marquardt et al., 2015; Sekiya and Suzuki, 2012). Given the molecular and partial 
histologic similarity to CCA, this potential subtype may be a distinct clinical entity and 
strongly warrants further study into its most beneficial classification. Furthermore, the 
complete lack of IDH mutations in otherwise standard HCC from the TCGA set (0/172) has 
implications about specific functions of mutant IDH in modulating liver cell identity and 
also underscores the benefit of combined molecular and histopathological diagnosis. 
Although previous studies also identified transcriptionally CCA-like HCC (Oishi et al., 
2012; Seok et al., 2012; Woo et al., 2010), our results identify IDH and FGFR2 perturbations 
as associated drivers linked to methylation, miRNA, and copy number similarities. Together, 
these findings highlight the uniqueness of IDH-mutant-driven cancers and the importance of 
defective chromatin regulation in the pathogenesis of CCA.
Improved molecular classification of cholangiocarcinoma is urgently needed, as 
heterogeneity presents a serious challenge to clinical management. Unlike cancers in which 
a few predominant oncogenic loci converge on a pathway, such as KRAS in PDAC or the 
mostly mutually exclusive BRAF, NRAS, and NF1 in melanoma, CCA is marked by a 
heterogeneous set of often-overlapping, lower-penetrance driver genes across diverse 
signaling pathways. This intertumoral heterogeneity is further exacerbated by geographically 
distinct molecular profiles and is modified by the presence or absence of liver fluke 
infestation and/or viral hepatitis, and by the anatomic location of the cancer. As examples, 
(1) extrahepatic CCAs have more SMAD4 mutations than iCCAs (Churi et al., 2014; Ong et 
al., 2012); (2) a Chinese study found a much lower incidence of IDH (5%), PBRM1 (1%), 
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and BAP1 (1%) mutations (Zou et al., 2014) in iCCAs; and (3) liver fluke- and/or viral 
hepatitis-positive cancers have a higher incidence of TP53 mutations and lower incidence of 
IDH mutations (Chan-On et al., 2013; Ong et al., 2012; Zou et al., 2014). In this study, we 
focused on intrahepatic and fluke- and hepatitis-negative CCA, which minimized 
heterogeneity and improved the ability to apply categorizing statistics. Although larger 
studies are needed to validate and identify further molecular subclasses, our results provide a 
proof of principle that subclasses of CCAs have distinct multi-level molecular characteristics 
that suggest potential therapeutic approaches.
In this regard, the enriched mitochondrial gene signature and coordinate increase in 
mitochondrial number in IDH mutant CCA is intriguing in light of prior work implicating 
mutant IDH in the impairment of multiple aspects of cell metabolism (Cuyàs et al., 2015; 
Grassian et al., 2014; Tateishi et al., 2015). These observations include 2HG-mediated 
disruption of components of the mitochondrial electron transport chain, and inhibition of 
reductive glutamine metabolism, a wild-type IDH1 -dependent process that is important for 
fatty acid synthesis in cells with dysfunctional mitochondria (Fu et al., 2015; Grassian et al., 
2014; Leonardi et al., 2012). The IDH mutant iCCA profile might thus reflect an adaptive 
response to mitochondrial dysfunction and/or an increased reliance on mitochondrial activity 
for tumor growth. The decrease in expression of chromatin regulators is also notable given 
the potential widespread effects of 2HG on epigenetic states via inhibition of TET family 
cytosine oxygenases and Jumonji domain family histone demethylases (Xu et al., 2011). 
However, the significance of this signature is difficult to interpret, since the genes 
contributing to the signature spanned all classes of chromatin regulators as well as 21 newly 
associated IncRNAs. Nevertheless, the discovery of distinct molecular features of IDH 
mutant iCCA is noteworthy in light of early clinical data using IDH1 -mutant-specific 
inhibitor (Burris et al., 2015). While promising, these data suggest that single-agent 
treatment with these drugs may not be sufficient to produce durable responses or remissions. 
Thus, targeting aspects of metabolism (e.g., using inhibitors of oxidative phosphorylation) or 
of chromatin regulation are tentatively suggested by our genomic findings as avenues for 
future research. Notably, prior work has suggested that BAP1, PBRM1, and ARID1A 
deficiency all result in sensitivity to EZH2 inhibition across cancer types (Kim et al., 2015; 
LaFave et al., 2015); the association of ARID1A methylation with IDH mutation opens the 
question of whether EZH2 inhibition might also be effective in this subtype. Collectively, 
our findings reveal distinct molecular characteristics of IDH mutant cholangiocarcinoma, 
offering insights and valuable multi-omics data as a springboard for future basic and 
translational research into this deadly disease.
Experimental Procedures
Cholangiocarcinoma (CCA) tumors were collected and shipped to a central Biospecimen 
Core Resource (BCR) between August 15, 2013 and January 20, 2014. Qualifying tumor 
samples were obtained from patients who had received no prior chemotherapy or 
radiotherapy treatment for their disease. Specimens were shipped overnight from 12 Tissue 
Source Sites (TSSs) using a cryoport that maintained an average temperature of less than — 
180°C. TSSs contributing biospecimens included Barretos Cancer Hospital (Barretos, 
Brazil); Emory University (Atlanta, GA, USA); Garvan Institute of Medical Research 
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(Darlinghurst, NSW, Australia); ILSbio, LLC (Chestertown, MD, USA); Mayo Clinic 
(Rochester, MN, USA); Sapienza University of Rome (Rome, Italy); Spectrum Health 
(Grand Rapids, MI, USA); University of Calgary Alberta Health Services (Calgary, AB, 
Canada); University of California - San Francisco (San Francisco, CA, USA); University of 
New Mexico (Albuquerque, NM, USA); University of North Carolina (Chapel Hill, NC, 
USA); Wake Forest University (Winston-Salem, NC, USA).
In addition to tumor samples, each frozen primary tumor specimen had a companion normal 
tissue specimen (blood or blood components, including DNA extracted at the TSS). 
Adjacent nontumor tissue was also submitted for a subset of cases (n = 20).
Cases were staged according to the American Joint Committee on Cancer (AJCC) staging 
system. Pathology quality control was performed on each tumor specimen and on adjacent 
normal tissue (where available) from a frozen section slide prepared either by the BCR or by 
the TSS. H&E-stained sections from each sample were made available on to a team of 
independent pathologists for review to: confirm consistency with CCA histology, confirm 
that the adjacent tissue specimen contained no tumor cells, and annotate various standard 
pathological parameters. Only tumor samples with ≥60% tumor nuclei, and %20% necrosis 
were submitted for nucleic acid extraction.
The data and analysis results can be explored through the TCGA Data Portal (https://gdc-
portal.nci.nih.gov/projects/TCGA-CHOL), the Broad Institute GDAC FireBrowse portal 
(http://firebrowse.org/?cohort=CHOL), and Memorial Sloan Kettering Cancer Center 
cBioPortal (http://www.cbioportal.org/study.do?cancer_study_id=chol_tcga#summary). 
Detailed experimental procedures are included in the Supplemental Experimental 
Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• IDH mutant CCAs have distinct mRNA, copy number, and DNA methylation 
features
• IDH mutant CCAs display high mitochondrial and low chromatin modifier 
gene expression
• IDH mutant CCAs methylate the ARID1A promoter and show low ARID1A 
expression
• Other IDH mutant liver cancers show multiplatform similarities to CCA
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In Brief
Farshidfar et al. present The Cancer Genome Atlas (TCGA) marker analysis of 
cholangiocarcinoma. Through multiplatform analyses, they identify a distinct subtype 
enriched for IDH mutants. This subtype shows increased mitochondrial and decreased 
chromatin modifier gene expression, including potential epigenetic silencing of ARID1A. 
Other IDH-mutant liver cancers molecularly resemble cholangiocarcinoma.
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Figure 1. Somatic Alterations in Cholangiocarcinoma
(A and B) Significantly mutated genes identified using the MutSigCV algorithm, and 
additional genes with chromosomal alterations, hotspot mutations (red font), and possibly 
functional mutations, grouped by pathway. (A) TCGA analysis sample set (n = 38). (B) 
Additional sample set (n = 15). Left, mutation amount and percentage, plus epigenetic 
silencing for CDKN2A. Top, overall number of mutations per megabase. Bottom, mutation 
spectra signatures. Dashed yellow line in upper panel indicates median mutations/megabase.
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Figure 2. mRNA Analysis of Cholangiocarcinoma Identified an IDH-Enriched Cluster
(A and B) Principal component analysis of RNA-seq expression data of 15,272 genes after 
exclusion of 541 normal liver genes. The heatmap in (A) shows the most strongly 
discriminant 973 genes (shared between the TCGA and the GSE26566 dataset) that define 
the three clusters. (B) Three-dimensional PCA plot of TCGA CCA samples. (C) 
Hierarchical clustering analysis of 40 samples from the CCA microarray dataset GSE26566, 
using the same 973 genes as in (A). Genes in heatmaps (A) and (C) are shown in the same 
order.
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Figure 3. IDH Mutant Cancers Are Enriched for a High Mitochondrial Signature and 
Mitochondrial DNA Count and a Low Chromatin Modifier Signature
(A) GSEA analysis identified mitochondrial and chromatin modifier genes as significantly 
differentially expressed in the IDH-mutant-enriched mRNA cluster 1. Selected pathways are 
shown, omitting genesets that show a high degree of gene membership overlap with the 
displayed pathways. Full results are available in Table S6. NES, normalized enrichment 
score; size, geneset size.
(B and C) Heatmaps of the most significant mitochondrial and chromatin-modifier genes for 
TCGA (B) and GSE26566 (C). TCGA samples are filtered for high purity (>0.65); 
unfiltered results are shown in Figure S9.
(D and E) Quantification of mitochondrial signature (D) and mitochondrial DNA (E) count 
for different mutational subgroups, showing high-purity samples only. No subgroup by itself 
is significantly different from all other samples, indicating only enrichments and not 
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exclusivity for high/low mitochondrial markers. Box and whisker plots show maximum and 
minimum bars.
(F) Pan-cancer correlation analysis of mitochondrial and chromatin modifier genes. For each 
cancer, the genes on the x and y axes are the same and in the same order. Red signifies high 
positive Spearman correlation values; green denotes high negative values for each gene-gene 
comparison. C, chromatin modifiers; M, mitochondrial genes. Genes are listed in Table S8.
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Figure 4. Cluster-of-Clusters Analysis of CCAs
(A) Unsupervised hierarchical clustering of copy number data. The clustering is performed 
on SCNAs that are determined by GISTIC analysis to be significantly altered, as shown in 
the lower heatmap.
(B) Unsupervised hierarchical clustering of DNA methylation data.
(C) The cluster-of-clusters analysis (COCA) was performed on the three platforms with the 
strongest degree of correlation (mRNA, copy number, and methyl-ation). Bottom, robustness 
scores indicating strength of cluster membership assignment for each sample. Selected 
information of interest is shown here; full clustering, genetic, clinical, and pathological data 
are available in Table S1.
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Figure 5. ARID1A Is Hypermethylated and Has Low Expression in the IDH COCA
(A and B) TCGA methylation (A) and RNA-seq (B) data for 24 genes (36 probes) that show 
both IDHmut-specific hypermethylation and downregulation in the IDH COCA subtype.
(C and D) Methylation (C) and microarray (D) data for the same 24 genes and 36 
methylation probes as in (A and B), in the publically available datasets GEO: GSE32079 and 
GSE26566.
(E) Scatterplot of TCGA methylation and RNA expression values for ARID1A.
(F) Location of the two ARID1A hypermethylated probes within the ARID1A promoter. 
ENCODE histone marks for H3K27Ac and H3K4me3 are shown.
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Figure 6. Cross-Cancer Analysis Comparing TCGA Cholangiocarcinoma, HCC, and Pancreatic 
Adenocarcinoma
(A) Tumor map analysis incorporating mRNA, methylation, and copy number showing 
proximity of each sample.
(B) COCA across miRNA, copy number, DNA methylation, RPPA, and Tumor Map for the 
three cancer types. Unsupervised clustering was performed within each data type across a 
cohort of 292 samples from CCA, HCC, and PDAC to derive cross-tumor subtypes (miRNA 
n = 4; copy number (CN) n = 5; DNA methylation (DNAmeth) n = 7; RPPA n = 6; tumor 
map n = 7; see Figure S6 for individual platform cluster solutions). Individual classification 
subtypes were then used as input for pan-tumor COCA analysis identifying three COCA 
classes (first bar; K1, light green; K2, dark blue; K3, light blue). Second annotation bar 
denotes histology type – CCA, HCCC, PDAC. Third bar indicates the CCA-specific subtype 
classification (ECC, METH2, Meth3, and IDH, cf. Figure 5). Fourth bar notes IDH1 
mutation status (red, R172 mutations; blue, R132 mutations; black, other mutations). Fifth 
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bar indicates samples with FGFR2 fusions. Sixth bar indicates CCA score, a median value of 
the 600 most-enriched genes in CCA (see C). The bottom heatmap indicates sample 
membership for each of the individual classification subtypes (black, subtype member; 
white, not a subtype member; gray, missing data). Each row is labeled by platform and 
subtype number.
(C) Six hundred genes enriched in cholangiocarcinoma-like HCC.
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Table 1
Patient Characteristics
Characteristics Number of Patients
Total number of patients 38
Median age at diagnosis (years) 66 (range 29–82)
Gender
Female 21
Male 17
ECOG PS
0 19
1 9
2 0
3 1
Unknown 9
Histologic Grade
G1 5
G2 21
G3 9
G4 2
Unknown 1
Resection status (R0/R1/Rx) 28/7/3
Tumor Stage
T1 19
T2 (T2a/T2b) 15 (2/5)
T3 4
Histologic Diagnosis
Intrahepatic 32
Extrahepatic/hilar 4
Mixed ICC/HCC 2
Lymph node status (N0/N1/Nx) 26/5/7
Metastatic disease (M0/M1/Mx) 30/4/4
Lymphovascular invasion (yes/no/unknown) 15/22/1
Perineural invasion (yes/no/unknown) 4/33/1
Elevated CA 19-9 (yes/no/unknown) 18/13/7
Race (white/Asian/black) 33/3/2
Country submitting tumor (USA/Canada/Italy/Brazil/Vietnam 30/4/2/1/1
Elevated CA 19-9 (yes/no/unknown) 18/13/7
Presence of fluke infection (Y/N) 0/38
ECOG, Eastern Cooperative Oncology Group.
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